Related Experiment Video
Updated: Sep 17, 2026

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
Published on: October 3, 2018
Renal Outcomes Following Autologous Stem Cell Transplantation in Dialysis-Dependent Patients With Multiple Myeloma: A
Maher Battat1, Ahmad Khursani1, Mohammedkhaled J Alhendi2
1Bone Marrow Transplantation and Leukemia Unit, An-Najah National University Hospital (NNUH), Nablus 44839, State of Palestine.
Background:
Multiple myeloma (MM) frequently causes renal impairment, and a subset of patients progresses to end-stage renal disease (ESRD) requiring dialysis. Dialysis dependence has historically been considered a relative contraindication to high-dose conditioning and autologous stem cell transplantation (ASCT). Emerging evidence indicates that ASCT may provide effective hematologic control and, in selected patients, renal recovery.
Methods:
We conducted a retrospective case series of five dialysis-dependent patients with MM who underwent ASCT at An-Najah National University Hospital. Demographic and clinical characteristics, transplant variables, supportive-care measures, infectious and noninfectious complications, hematologic recovery, admission and discharge laboratory values, and short-term outcomes were extracted from the medical records.
Results:
The five patients had a mean age of 56 years and received reduced-dose melphalan (140 mg/m2), followed by peripheral-blood CD34+ cell infusion. The mean CD34+ collection and infusion doses were 4.3 × 106/kg and 4.1 × 106/kg, respectively. All patients achieved engraftment; mean neutrophil and platelet engraftment occurred on Days 13.0 and 19.4, respectively. Four patients (80%) developed neutropenic fever. Clostridioides difficile and Staphylococcus epidermidis were the most frequently documented pathogens. Two patients developed central line-associated bloodstream infection and septic shock. No 100-day treatment-related mortality occurred. Creatinine and blood urea nitrogen remained elevated, and all patients continued maintenance hemodialysis at discharge.
Conclusions:
ASCT was feasible in carefully selected dialysis-dependent patients with MM and was associated with timely hematologic recovery and no 100-day treatment-related mortality. Infectious complications and vascular-access management remain major clinical concerns. Larger prospective studies are needed to define long-term renal outcomes and predictors of dialysis independence.
Related Concept Videos
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell types that...
Kidney Transplant I: Introduction
